Compare PSEC & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PSEC | PHAT |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | 8 | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 969.8M |
| IPO Year | N/A | 2019 |
| Metric | PSEC | PHAT |
|---|---|---|
| Price | $2.12 | $11.52 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $2.50 | ★ $19.83 |
| AVG Volume (30 Days) | ★ 4.8M | 1.2M |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | ★ 20.07% | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | N/A | $93.04 |
| Revenue Next Year | N/A | $58.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $2.11 | $8.03 |
| 52 Week High | $3.48 | $18.31 |
| Indicator | PSEC | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 36.56 | 53.92 |
| Support Level | $2.11 | $9.95 |
| Resistance Level | $2.37 | $11.65 |
| Average True Range (ATR) | 0.05 | 0.68 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 5.82 | 46.35 |
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests mainly in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.